- Home
- PVL vs MAIA Comparison
PVL vs MAIA Comparison
Compare PVL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | MAIA |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PVL | MAIA |
|---|---|---|
| Price | $1.89 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.6K | ★ 454.0K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 19.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $3,511,891.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.20 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $0.87 |
| 52 Week High | $2.04 | $2.74 |
Technical Indicators
Market Signals| Indicator | PVL | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 53.94 |
| Support Level | $1.82 | $1.07 |
| Resistance Level | $1.83 | $1.25 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 86.67 | 55.93 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.